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ABSTRACT
Developing a safe and effective H7N9 influenza vaccine was initiated in early 
spring 2013, following human infections with a novel avian influenza A (H7N9) 
virus. In this study, a candidate H7N9 vaccine seed strain is produced using reverse 
genetics, with HA and NA derived from a human H7N9 virus and the remaining genes 
from the PR8 backbone virus which grows well in eggs. We verified that the virulence 
and transmissibility of the recombinant H7N9 vaccine seed strain were decreased as 
compared to wild-type H7N9 virus, to levels comparable with PR8. Using the seed 
virus, we produced a monovalent split influenza A (H7N9) MF59-adjuvanted vaccine 
that was immunogenic in mice. Our H7N9 vaccine is selected for clinical investigation 
and potential human use. To assess the safety of our H7N9 vaccine, we performed 
acute toxicity, repeated dose toxicity and active systemic anaphylaxis tests. Our 
results showed that, under the conditions used in this study, the NOEAL (no obvious 
adverse effect level) was 30 μg/0.5 mL.
INTRODUCTION
The outbreak of a previously unrecognized novel 
reassortant avian influenza A (H7N9) virus in China 
in March 2013 provoke people's attention [1], the 
outbreak rapidly spread to other Chinese provinces and 
municipalities [2]. World Health Organization has reported 
a total of 571 cases, 212 deaths (37.1%) by February 23, 
2015 [3].
Antiviral drugs are critical tools for treating infection 
with the novel H7N9 virus; however, this approach is 
fraught with budgetary restrictions and concerns regarding 
misuse and the development of drug resistance. A more 
feasible requires the production of safe and effective 
vaccines [4]. The ideal influenza vaccine seed virus 
must be low pathogenic for safe use in a manufacturing 
setting. The application of plasmid-based reverse genetics 
systems did aid the development and production of 
vaccines greatly [5, 6], it offers the benefits including 
the removal of pathogenic traits at the plasmid stage [7]. 
We applied reverse genetics technologies to construct 
candidate viruses that harbor the hemagglutinin (HA) and 
neuraminidase (NA) glycoproteins of A/Zhejiang/DTID-
ZJU01/2013(H7N9), with the remaining genes derived 
from A/Puerto Rico/8/34(H1N1; PR8). There are several 
H7N9 seed strains, most of them were produced using 
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the HA and NA sequences from the A/Shanghai/2/2013 
and A/Anhui/1/2013 strains [8]. Importantly, The A/
Zhejiang/1/2013 strain applied in our vaccine was used 
for the first time. Accordingly, our research was conducted 
to evaluate recombinant clones in BALB/c mice and 
ferrets to determine whether the recombinants displayed 
desirable characteristics including lower virulence and 
transmissibility. The development of vaccines against H7-
containing subtypes have been hampered on account of the 
poor immunogenicity [9–10]. The oil-in-water adjuvant 
MF59, which we have paired with our split virus vaccine, 
has been reported to enhance efficacy, permit dose sparing, 
lower the antigen dose and improve the antibody response 
that required to induce protection [11, 12]. In contrast, 
adding classic alum to subunit influenza or split vaccines 
has only been reported to improve it to a small extent 
[13, 14].
The safety profiles of vaccines continue to undergo 
considerable scrutiny, with a variety of issues raised 
following the withdrawal of a tetravalent rhesus-human 
reassortant rotavirus vaccine, RRV-TV, in 1999 [15]. 
Moreover, vaccines are typically given to a large number 
of both healthy individuals and vulnerable populations, 
including infants and young children [16]. Vaccines 
fall within the scope of medicinal products, and as such 
must undergo strict preclinical safety evaluation prior 
to licensing. This MF59-adjuvanted split H7N9 vaccine 
prepared from recombinant virus has been proven 
immunogenic and has shown prophylactic efficacy against 
A/Zhejiang H7N9 virus in preclinical studies [17]. Here, 
preclinical safety testing including acute toxicity, repeated 
dose toxicity and active systemic anaphylaxis tests were 
performed on our vaccine to assess the safety of the 
vaccine for potential clinical application.
RESULTS
Virulence and transmissibility of vaccine 
seed virus
The pathogenicity of different viruses was compared 
using the quantitative estimation minimal lethal dose 
(MLD50). The laboratory strain PR8, caused morbidity 
and mortality in infected mice, with a MLD50 of 10-
3.5/0.05 mL. The wt H7N9 virus was highly pathogenic in 
mice (MLD50, 10-0.7/0.05 mL), whereas the pathogenicity 
of recombinant H7N9 vaccine seed was attenuated 
(MLD50, 10-1.6/0.05 mL), compared with wt H7N9 virus.
No ferret deaths occurred in any of the six groups. 
In both the wt H7N9 and PR8 virus infection groups, we 
observed reduced locomotor activity and typical viral 
upper respiratory symptoms such as sneezing and runny 
nose beginning around 3 dpi and progressing until 8 dpi. 
Respiratory symptoms were observed in one ferret in 
the H7N9 vaccine seed virus infection group at 7 dpi, 
but disappeared within 24 h. One and two ferrets in the 
wt H7N9 virus transmission group were found to have 
clinical symptoms at day 6 and day 7, respectively, after 
housing with infected ferrets, with all clinical symptoms 
disappearing by day 10. No obvious clinical symptoms 
were observed in the other two transmission groups. These 
observations support that the wt H7N9 virus can transmit 
by aerosol, causing mild symptoms in ferrets, while the 
recombinant H7N9 vaccine seed virus does not.
We weighed the three infection groups before 
infection and again at 2, 4, 6, 8, 10, 12 and 14 dpi, and 
the three transmission groups before caging together with 
the infection groups and again on days 2, 4, 6, 8, 10, 12 
and 14 after caging together. Total body weight throughout 
the course of infection (14 days) for each group is shown 
in Figure 1A. A trend towards a reduction in weight at 
1 dpi was observed in all three infection groups and 
continued until day 8 dpi before reaching a plateau. There 
was no significant decrease in body weights in the H7N9 
vaccine seed virus transmission group or PR8 transmission 
group. Ferrets in the wt H7N9 virus transmission group 
started losing weight at day 2 after caging together, with 
weights remaining unchanged at days 4, 6 and 8, and then 
increasing. No significant differences in body weight (p > 
0.05) were observed across the three infection groups or 
the three transmission groups.
Body temperature was assessed twice daily and 
found to fluctuate between the morning and the evening 
(Figure 1B and 1C). The morning temperatures of the 
three infection groups increased at 2, 6, and 10 dpi. Both 
morning and afternoon temperatures peaked at 2 dpi. The 
morning temperatures of the three transmission groups 
fluctuated upwards at day 1 and persisted until day 6 after 
caging together. Body temperatures of the H7N9 vaccine 
seed virus and PR8 transmission groups fluctuated within 
the physiological temperature range with no significant 
differences observed. The temperatures of the wt H7N9 
virus transmission group increased at day 2 and day 6 after 
caging together with mean temperatures of 39.3 ± 0.1°C 
and 39.2 ± 0.4°C, respectively.
In the wt H7N9 infection group, a viral load of 4.71 
log10 ~ 6.65 log10 copies/mL was detected from nasal 
turbinate swabs at 1~5 dpi by qRT-PCR (Figure 1D). One 
ferret continued to shed virus until 7 dpi. The period of 
virus shedding for the H7N9 vaccine seed infection group 
and the PR8 infection group was similar, up to 5 dpi, 
with viral loads of 4.32 log10 ~ 6.60 log10 copies/mL 
and 4.55 log10 ~ 6.39 log10 copies/mL respectively. The 
viral load of the H7N9 vaccine seed infection group was 
significantly lower than the wt H7N9 virus infection group 
(p < 0.05) and PR8 infection group (p < 0.05). No virus 
was detected from the nasal turbinate swabs of the H7N9 
vaccine seed transmission group or PR8 transmission 
group. Two ferrets from the wt H7N9 transmission group 
showed positive viral loads (4.51 log10 ~ 7.28 log10 
copies/mL) from 4 to 8 dpi. One of the ferrets had a 
detectable viral load for 7 days.
Oncotarget81014www.impactjournals.com/oncotarget
Virus titers from the H7N9 vaccine seed infection 
group were significantly lower than the wt H7N9 virus 
infection group (p < 0.05; Figure 1E), especially at 1 and 
5 dpi. Titers were also lower than in the PR8 infection 
group (p < 0.05), especially at 3 dpi. The peak of viral 
shedding from ferrets in the transmission groups was 
between 5 and 8 dpi, which was consistent with the 
timeframe of virus shedding from ferrets in the infection 
groups. The virus titers from nasal turbinate swabs of 
the wt H7N9 transmission group were even higher than 
from the wt H7N9 infection group at certain times during 
observation period; the peak virus titer from the wt H7N9 
virus transmission group was 4.92 log10 TCID50/mL, 
while that of the wt H7N9 virus infection group was 4.30 
log10 TCID50/mL. The virus titer of the H7N9 virus seed 
transmission group was significantly lower than the other 
two transmission groups (both p < 0.05).
The serum HI titers of all the groups were negative 
at 3 dpi and 14 dpi (Figure 1F). The serum HI titers varied 
across the three infection groups with the PR8 infection 
group showing the highest titers (20480), followed by the 
H7N9 seed infection group (453), and finally the wt H7N9 
infection group (113). Fourteen days after caging together, 
the HI titers of 2 ferrets in the wt H7N9 transmission 
group were 80 and 160 respectively, which suggests 
these two ferrets may have been infected through aerosol 
transmission.
The extent and characteristics of the lesions were 
variable among the three infection groups (Figure 2). 
Pulmonary vasodilation occurred in all three infection 
groups at 3 dpi and more serious damage such as focal 
widened alveolar septum, epithelial cell degeneration and 
shedding and inflammatory cell infiltration were detected 
in wt H7N9 virus infected ferrets. Lesions were mitigated 
in all these groups at 14 dpi. The wt H7N9 infected ferrets 
showed the most severe lesions at both 3 dpi and 14 dpi. 
No inflammatory reactions or other histopathological 
changes were observed in any of the following tissues: 
spleen, intestines, liver, heart, kidney, olfactory bulb and 
brain.
Toxicity of the H7N9 split vaccine
There were no unscheduled deaths during the 
course of the study. No vaccine-related effects on clinical 
signs, body weight (Figure 3), food consumption, 
ophthalmologic examinations, coagulation, urinalysis, 
body temperature or local tolerance were observed.
Acute toxicity studies showed that NEUT and WBC 
in both males and females from group 3 (H7N9 split 
virus with MF59 adjuvant) and group 4 (MF59 adjuvant 
control) increased, with values being comparable to the 
NS (normal saline) control group (group 1; Table 1A). The 
albumin/globulin (A/G) ratio in both males and females 
Figure 1: Body weight, body temperature, viral load, viral titers and serum HI titer of ferrets from the virulence 
and transmissibility test. A. Weight of ferrets up to 14 dpi. B. Morning temperature of the six groups over the course of infection. C. 
Afternoon temperatures of the six groups. D. Viral loads in the six groups. Turbinate swabs were collected and viral load determined by 
qRT-PCR. The geometric mean of the titers is displayed. E. Virus titers in the six groups. The titers in the swabs were determined by end-
point titration in MDCK cells. F. HI titers in serum 14 dpi determined by HI test.
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in group 3 and group 4 decreased (Table 1B). There were 
no H7N9 avian influenza vaccine-related organ weight 
changes, H7N9 avian influenza vaccine with adjuvant, 
or adjuvant-related organ weight changes observed in the 
spleen. Compared with the NS control group, the mean 
absolute and relative (to brain and body weight) weight of 
the spleen of females in the group treated with adjuvant 
increased slightly (22% to 24%; Table 1C), without gross 
lesions. All spleen weights for other animals were within 
the range of the NS control groups with the exception one 
male animal in group 4 which had a higher spleen weight. 
Similar changes did not occur in other males; therefore, it 
was considered unrelated to the study treatments.
NEUT and EOS in both males and females 
undergoing repeated dose toxicity testing in group 3 
(H7N9 split virus with MF59 adjuvant) and group 4 
(MF59 adjuvant control) increased after dosing on day 
17 and day 32 (Table 2A). A/G ratio in both males and 
females in group 3 and group 4 decreased after dosing 
on day 17 and day 32, when compared to the NS control 
(Table 2B). The ratio change was due to a significant 
increase in globulin, and decrease in albumin. In the 
dosing phase, mean absolute and relative (to body and 
brain) spleen weights were increased in males and 
females treated with the influenza vaccine with adjuvant 
and increased to statistically significant levels (p < 0.05) 
Figure 2: Lung histopathology of ferrets inoculated intranasally inoculated with 106 TCID50 of wt H7N9 virus, H7N9 
vaccine seed or PR8 at 3 dpi and 14 dpi. Multiple 4-μm-thick sections were stained with H&E. Original magnification A-C. ×200, 
D-F. ×100.
Figure 3: Weight change of rats from the A. acute toxicity test, B. repeated dose toxicity test, and C. active systemic 
anaphylaxis test. The arrows indicate the immunization times.
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Table 1: Hematology: NEUT and WBC; Serum Chemistry: ALB (Albumin), GLB (Globulin) and A/G (%) and 
Spleen weight (absolute weight, spleen/body ratio and spleen/brain ratio) in both males and females rats from acute 
toxicity test in group 2 (H7N9 split virion), group 3 (H7N9 split virion with MF59 adjuvant) and group 4 (MF59 
adjuvant control) with values being comparable to the NS control group (Group 1) 
Table 1A
Dose (mg/kg) Study Day
30 μg/0.5 mL
H7N9
Male:10/5, 
Female:10/5
15 μg/0.25 mL H7N9
+ MF59 0.25 mL
Male:10/5, Female:10/5
0.25 mL PBS
+ MF59 0.25 mL
Male:10/5, Female:10/5Number of animals
NEUT (103/μL) (%)
Day 2 ↓0.5 ↑12.65 ↑402.84*** ↑706.08*** ↑366.95*** ↑765.21***
Day 14 ↓36.75 ↑3.32 ↑4.3 ↑42.71 ↑0.72 ↑14.57
WBC (103/μL) (%)
Day 2 ↓14.68 ↑7.84 ↑26.25 ↑61.33** ↑17.69 ↑77.25**
Day 14 ↓40.43** ↑7.67 ↓19.38 ↑0.87 ↓26.79* ↑18.02
Table 1B
Dose (mg/kg) Study Day
30 μg/0.5 mL
H7N9
Male:10/5, 
Female:10/5
15 μg/0.25 mL H7N9
+ MF59 0.25 mL
Male:10/5, Female:10/5
0.25 mL PBS
+ MF59 0.25 mL
Male:10/5, Female:10/5Number of animals
Day 2
ALB (g/L) ↓2 − ↓1.9 ↓0.8 ↓2 ↓2.1
GLB (g/L) ↓1.6 ↓0.2 ↑1.7 ↑2.1 ↑1.8 ↑2.3
A/G (%) ↑0.62 ↑0.88 ↓11.11*** ↓9.34** ↓12.03*** ↓12.9***
Day 14
ALB (g/L) ↓1.1 ↓1.3 ↓.1.8 ↓3.5 ↓0.6 ↓2.2
GLB (g/L) ↓0.8 ↑1.6 ↓0.9 ↑0.6 ↓0.6 ↑1.8
A/G (%) ↑0.24 ↓2.71 ↓1.72 ↓4.02 ↑0.8 ↓3.77
Table 1C
Dose (mg/kg) Index
30 μg/0.5 mL
H7N9
Male:10/5, 
Female:10/5
15 μg/0.25 mL H7N9
+ MF59 0.25mL
Male:10/5, 
Female:10/5
0.25 mL PBS
+ MF59 0.25 mL
Male:10/5, Female:10/5Number of animals
Spleen weight
Spleen (g) ↓0.0231 ↑0.0227 ↓0.0415 ↑0.0245 ↓0.0688 ↑0.1106
Spleen/Body (10-3) ↓0.0033 ↑0.0476 ↓0.0805 ↑0.0506 ↓0.2374 ↑0.4543
Spleen/Brain ↓0.0008 ↑0.002 ↓0.0093 − ↓0.0119 ↑0.0537
“−” indicates that all changes were small in magnitude or were comparable to the control groups. ***, ** and* indicate p < 
0.001, 0.01, and 0.05, respectively when compared with the NS control. (A) NEUT and WBC changes after dosing on day 2 
(B) Serum ALB, GLB and A/G (%) changes of after dosing on day 2 (C) Spleen weight (absolute weight, spleen/body ratio 
and spleen/brain ratio) changes after dosing on Day 14.
in females treated with adjuvant alone (Table 2C). The 
weight change of the spleen was associated with minimal 
extramedullary hematopoiesis in some females. Following 
the recovery period, the hematology (NEUT and EOS), 
serum chemistry (A/G ratio) and spleen weight changes 
had resolved, with values comparable to the NS control 
group.
At the dosing phase of repeated dose toxicity testing, 
treatment with the influenza vaccine with adjuvant, and/or 
treatment with adjuvant alone, caused mixed cell infiltration 
in the interstitium of the intramuscular injection sites (Figure 
4A). The severity of this change was slightly higher in 
animals treated with the influenza vaccine with adjuvant 
than in those treated with adjuvant alone. We also observed 
lymphoid hyperplasia in the follicles and plasmacytosis in 
the medulla of the lymph nodes (popliteal and inguinal; 
Figure 4B and Figure 4D). These lymph nodes were the 
draining nodes for the injection and these changes were an 
expected effect of the treatment. Mixed cell infiltration in the 
perinodular connective tissue of the popliteal lymph nodes, 
in the interstitium of the skeletal muscle (biceps femoris, 
Figure 4C), and in the epineurium surrounding the nerves 
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Table 2: Hematology: NEUT and EOS; Serum Chemistry: ALB (Albumin), GLB (Globulin) and A/G (%) and spleen 
weight (absolute weight, spleen/body ratio and spleen/brain ratio) in both male and female rats from repeated dose 
toxicity testing in group 2 (H7N9 split virion), group 3 (H7N9 split virion with MF59 adjuvant) and group 4 (MF59 
adjuvant control) with values being comparable to the NS control group (group 1)
Table 2A
Dose (mg/kg)
Study Day
30 μg/0.5 mL
H7N9
Male:10/5, Female:10/5
15 μg/0.25 mL H7N9
+ MF59 0.25 mL
Male:10/5, Female:10/5
0.25 mL PBS
+ MF59 0.25 mL
Male:10/5, Female:10/5Number of animals
NEUT (103/μL) (%) Day 17 −a − ↑50.14*** ↑143.29*** ↑54.96*** ↑75.58***
Day 32 − − ↑44.83 ↑66.75* ↑7.92 ↓0.48
Day 57 − − ↑2.83 ↓32.56 ↑29.09 ↓28.37
EOS (103/μL) (%) Day 17 − − ↑149.73*** ↑227.27*** ↑98.46*** ↑145.46***
Day 32 − − ↑366.67*** ↑613.04*** ↑69.44** ↑215.22***
Day 57 − − ↑40 ↑83.33 ↑20 ↑8.33
Table 2B
Dose (mg/kg)
Study Day
30 μg/0.5 mL
H7N9
Male:10/5, Female:10/5
15 μg/0.25 mL H7N9
+ MF59 0.25 mL
Male:10/5, Female:10/5
0.25 mL PBS
+ MF59 0.25 mL
Male:10/5, Female:10/5Number of animals
Day 17 ALB (g/L) ↑0.1 ↓2.1 ↓3.2*** ↓5*** ↓2.4*** ↓4.5***
GLB (g/L) ↓0.8 ↓1 ↑3*** ↑2.4*** ↑2.6*** ↑1.3
A/G (%) − − ↓17.05*** ↓18.36*** ↓14.06*** ↓14.07***
Day 32 ALB (g/L) ↓0.4 ↓0.8 ↓2.2*** ↓4** ↓1.8*** ↓3.1*
GLB (g/L) ↓0.6 ↑0.3 ↑3.7*** ↑4.8*** ↑1.6* ↑1
A/G (%) − − ↓18.60*** ↓24.56*** ↓10.72*** ↓11.53***
Day 57 ALB (g/L) ↑0.3 ↓1.7 ↑0.3 ↓1.3 ↓0.4 ↑2.3
GLB (g/L) ↓0.7 ↓0.4 ↑2.5 ↑3.3 ↓1.2 ↑1.1
A/G (%) − − ↓8.06 ↓11.57* ↑3.70 ↑2.57
Table 2C
Dose (mg/kg)
Index
30 μg/0.5 mL
H7N9
Male:10/5, Female:10/5
15 μg/0.25 mL H7N9
+ MF59 0.25 mL
Male:10/5, Female:10/5
0.25 mL PBS
+ MF59 0.25 mL
Male:10/5, Female:10/5Number of animals
Day 32 Spleen (g) ↑0.0638 ↑0.0201 ↑0.1103 ↑0.0725 ↑0.0399 ↑0.0849*
Spleen/Body (10-3) ↑0.1304 ↑0.0617 ↑0.2348 ↑0.2504 ↑0.0343 ↑0.3262*
Spleen/Brain ↑0.0203 ↑0.0203 ↑0.0421 ↑0.0421* ↑0.0194 ↑0.0399*
Day 57 Spleen (g) ↓0.0019 ↑0.1035 ↓0.0755 ↓0.0079 ↓0.0421 ↓0.0102
Spleen/Body (10-3) ↓0.0138 ↑0.0175 ↓0.0978 ↑0.0646 ↓0.0082 ↓0.0195
Spleen/Brain ↓0.0138 ↑0.0152 ↓0.0329 ↑0.0052 ↓0.0189 ↑0.0033
 “−” means that all changes were small in magnitude or were comparable with the control groups. ***, **and* indicate p < 
0.001, 0.01, and 0.05, respectively when compared with the NS control. (A) NEUT and EOS changes after dosing on Day 
17, 32 and 57. (B) Serum ALB, GLB and A/G (%) changes after dosing on Day 17, 32 and 57. (C) Spleen weight (absolute 
weight, spleen/body ratio and spleen/brain ratio) changes after dosing on Day 32 and 57.
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(Figure 4E) was observed. These findings were considered 
an extension of the local injection reaction because of 
the close proximity to the intramuscular injection site(s). 
Extramedullary hematopoiesis in the spleen (Figure 4F) 
was also observed, which correlated with increased organ 
weights. This change was considered to be an adaptive 
response to the inflammatory reaction incited by the 
injection of adjuvant or influenza vaccine with adjuvant, 
which correlated with the NEUT and EOS increase in 
hematology analysis and A/G decrease in serum chemistry. 
At the end of recovery phase (Figure 5), only mononuclear 
cell infiltration and fibroplasias at the injection sites, and 
lymphoid hyperplasia and plasmacytosis in the popliteal 
lymph nodes were noted, indicating most of the changes 
had resolved following the recovery phase, which 
correlated with the recovery observed in the hematology 
and serum chemistry results.
No abnormalities were noted during the induction 
phase of the active systemic anaphylaxis test. On the 
days of challenge dosing, no abnormalities were recorded 
for groups 1-4 immediately following the challenge 
injection, up to 3 h after injection. For animals in group 
Figure 4: At day 32 (dosing phase) of the repeated dose toxicity test, H&E staining was performed of various 
organs from rats treated with H7N9 vaccine with MF59 adjuvant or NS control. A. Intramuscular injection sites (original 
magnification, ×40), B. popliteal lymph nodes (original magnification, ×200), C. biceps femori (original magnification, NS control, ×40, 
H7N9 + MF59, ×200), D. inguinal lymph nodes (original magnification, ×40), E. sciatic nerve (original magnification, ×100), F. spleen 
(original magnification, ×40).
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5 (albumin, positive control), strong signs of labored 
respiration, unsteady gait and/or purpura, as well as weak 
signs of restlessness, piloerection, and nose scratching, 
were observed in six animals within 5 min of intravenous 
challenge.
Hematology and clinical pathology changes were 
restricted to those animals receiving the vaccine with 
adjuvant or adjuvant alone. These included significant 
increases in WBC and NEUT in the acute toxicity test, 
increases in EOS and NEUT in repeated dose toxicity 
testing and decreases in the A/G ratio. These changes were 
considered an immune response to the adjuvant. There 
were no macroscopic findings in the observation period. 
There were no organ weight changes or microscopic 
findings that were attributed to administration of the 
influenza vaccine alone. During repeated dose toxicity 
testing, increased mean absolute and relative spleen 
weights were observed in males and females treated 
with influenza vaccine with adjuvant and statistically 
significant increases were observed in females treated 
with adjuvant alone. This change correlated with minimal 
extramedullary hematopoiesis in some females, and was 
considered to be an adaptive response to the inflammatory 
reaction incited by the injection of influenza vaccine 
with adjuvant or adjuvant alone. Consequently, under the 
conditions in this study, the NOEAL (no obvious adverse 
effect level) was determined to be 30 μg/0.5 mL.
DISCUSSION
Previous studies have reported the safety of vaccines 
prepared using alternative seed strains [18]. However, 
most of the studies are clinical reports and evaluate only 
the clinical adverse events. Systematic reports including 
potential physiological and pathological changes are rare. 
Pathogenicity experiments in mice and ferrets confirmed 
that we successfully developed a safe vaccine seed strain 
which demonstrated lower virulence and transmissibility 
as compared with wt H7N9 virus. Furthermore, preclinical 
safety and toxicity tests of the MF59-adjuvanted split 
influenza vaccine provided no indication of a potential risk 
of administering the vaccine up to 30 μg/0.5 mL dose in 
the experimental animals.
We applied reverse genetics to construct candidate 
vaccine which contained the HA and NA genes of A/
Zhejiang/DTID-ZJU01/2013 virus and six genes that 
encoded internal proteins from the PR8 virus. According 
to a previous analysis of antigenic epitopes of avian 
influenza A (H7N9) viruses [19, 20], the antigenic 
variation of HA fragments between A/Zhejiang H7N9 
virus and other H7N9 viruses is minor. The H7N9/PR8 
virus has many desirable characteristics, including that 
it can be parenterally administered in an inactive form. 
Moreover, the lack of pathogenicity or infectivity in 
chickens should provide for the production of an egg-
Figure 5: At day 57 (recovery phase) of the repeated dose toxicity test, H&E staining was performed of intramuscular 
injection sites and popliteal lymph nodes from rats treated with H7N9 vaccine with MF59 adjuvant. Intramuscular 
injection sites, magnification ×40 A., ×400 B. Popliteal lymph nodes magnification ×40 C., ×200 D.
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based vaccine. We utilized a ferret (Mustela putorius furo) 
model to investigate virulence and transmissibility of this 
H7N9 vaccine seed strain because they are susceptible to 
natural infection and develop respiratory disease and lung 
pathology similar to humans [21]. Pathogenicity studies 
showed that the H7N9/PR8 reassortant was not highly 
virulent, and transmissibility for mice or ferrets, which 
was in accordance with ideal influenza vaccine seed strain 
requirements.
Unfortunately, an adjuvant is demanded because 
of the comparatively week immunogenicity of split 
vaccines [9, 22]. MF59 was applied because according 
to the report that it can obviously reduce the antigen 
requirements of the split influenza vaccine and can achieve 
the protective effect with a single dose [10, 23]. Ideal 
adjuvant properties include a strong enhancement of the 
immune response, as well as a favorable safety profile. 
Similar to the classic immunoadjuvant Al(OH)3, the safety 
and potency of MF59 has been described in many human 
clinical trials [24]. The safety of vaccines must be strictly 
assessed, and every vaccine batch must be examined 
by the National Control Laboratories according to the 
guidelines published by each country. However, rare cases 
of the development of autoimmune diseases following 
influenza vaccinations with MF59 adjuvant [25] and alum-
associated macrophagic myofasciitis syndrome [26] have 
been reported. The preclinical study reported here supports 
the good safety of the MF59-adjuvanted H7N9 split 
vaccine by suggesting a lack of toxicological findings. 
Toxicity tests of the split H7N9 vaccine in rats and guinea 
pigs indicated a large safety margin. A dose of a high 
concentration of the MF59-adjuvanted H7N9 split vaccine 
by the intramuscular route in rats showed no effects at 
levels far above a typical clinical dose volume of 0.5 mL 
for these types of materials. Therefore, on a weight-to-
weight basis, a safety margin of approximately 240-fold 
(rat = 250 g) was achieved for a 60 kg person. Only after 
repeated intramuscular administration of the vaccine with 
MF59 or MF59 alone in rats did we observe changes in 
hematology and clinical pathology, and these changes 
were considered an immune response to the adjuvant or 
adaptive response to the inflammatory reaction. Overall, 
the vaccine candidate showed no toxicological findings of 
significance at levels greatly in excess of those proposed 
for clinical use. However, the causes of clinical adverse 
events are often unclear, and careful attention should be 
paid especially during the use of concomitant medications.
In conclusion, the comprehensive preclinical 
evaluation program conducted here documented the safety 
of the recombinant H7N9 vaccine seed strain and safety of 
the intramuscular MF59-adjuvanted split influenza vaccine 
in animal models. We believe this MF59-adjuvanted 
H7N9 split vaccine is able to protect against H7N9 virus 
without major HA antigenic drift. Further human testing 
will be needed to determine whether it could represent a 
candidate vaccine.
MATERIALS AND METHODS
Ethics statement
Research has been carried out in accordance with 
the ethical standards, and according to the Declaration 
of Helsinki and national and international guidelines. 
The investigation has been approved by the authors' 
institutional review board.
Animals, adjuvant and cell lines
Six-week-old BALB/c mice and 4- to 6-month-
old castrated male pet ferrets (Mustela putorius furo) 
were purchased from the Institute of Laboratory Animal 
Science, Chinese Academy of Medical Sciences. Six-
week-old rats were supplied by BioLASCO Taiwan Co., 
Ltd. Four- to six-week-old guinea pigs were provided 
by Charles River (Beijing, China). We housed animals 
in the departmental animal facility under the following 
requirements: temperature 22 ± 3°C, humidity 65 ± 
5%, and a 12 h light/dark cycle. The animals were fed a 
standard diet and water ad libitum, and were acclimatized 
for one week prior to the experiments. MF59 adjuvant was 
kindly provided by Tianyuan Bio-Pharmaceutical, which 
is affiliated with Novartis Vaccine Inc. The non-permissive 
renal canine epithelial cell line MDCK was obtained from 
ATCC (Rockville, MD, USA). All the tests performed 
conformed to Good Laboratory Practice (GLP).
Virus preparation
When using live influenza virus, we performed it in 
a biosafety level (BSL) 3 laboratory according to standard 
BSL3 guidelines. The reassortant virus was constructed 
using plasmid-based reverse genetics through transfection 
of eight individual plasmids into Vero cells [5, 6]. The 
plasmids harbored the HA and NA genes from the A/
Zhejiang/DTID-ZJU01/2013(H7N9) virus, which was 
isolated from a patient in Zhejiang Province of China in 
2013, and six internal genes from PR8. These viruses were 
propagated in specific-pathogen-free (SPF), embryonated 
chicken eggs and harvested, clarified, ultrafiltrated, zonal 
centrifuged, purified, cleaved, sterilization filtered and 
identified. All production processes were completed in 
a sterile workshop at Tianyuan Bio-Pharmaceutical in 
accordance the requirements of China Food and Drug 
Administration (CFDA) standard.
Vaccine seed virus MLD50 determination
Titrations of wild-type (wt) H7N9 virus (A/
Zhejiang/DTID-ZJU01/2013), the H7N9 vaccine seed (A/
ZJU01/PR8/2013) and a PR8 virus control were performed 
by intranasal inoculation of 13 to 14 g BALB/c mice with 
50 μL of virus at 10-fold serial dilutions. MLD50 in mice 
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was determined in groups of six mice. The MLD50 was 
calculated using the Reed and Muench method [27].
Virulence and transmissibility of the vaccine 
seed virus
The wt H7N9 virus, H7N9 vaccine seed virus 
and PR8 virus control were tested for virulence and 
transmissibility in total of 24 (350 g to 900 g) ferrets. 
The ferrets were divided into six groups for infection 
testing (wt H7N9 virus infection, H7N9 vaccine seed 
virus infection and PR8 virus infection), or transmission 
testing (wt H7N9 virus transmission, H7N9 vaccine seed 
virus transmission and PR8 virus transmission). Ferrets 
were housed individually. Four ferrets per infection group 
were inoculated with 106 TCID50 of virus. On day 1 post-
infection (dpi), a naïve ferret was introduced into each 
cage with the inoculated ferrets to measure direct contact 
transmission. All animals were observed for clinical 
signs of respiratory disease twice daily. Body weights 
were recorded and turbinate swabs collected every other 
day. Ferrets in the three infection groups were sacrificed 
(two at each time point) at 3 dpi and 14 dpi and lungs 
were removed, fixed in 10% buffered formalin, and 
embedded in paraffin. Blood samples were collected 
just prior to sacrifice, and serum samples were tested for 
hemagglutination inhibition (HI) titers. Viral load and viral 
titers in the lung (each lobe), turbinate, olfactory bulb, 
brain (anterior and posterior), spleen and duodenum were 
determined by quantitative real-time PCR and end-point 
titration in MDCK cells respectively. Lung (each lobe), 
spleen, intestines, liver, heart, kidney, olfactory bulb, brain 
(anterior and posterior), and other organs were reserved 
for pathological examination. In each transmission group, 
the period of infection, viral load and viral titers were 
determined in the same manner as described above. HI 
titers were examined at 14 days post-conversion.
HI test
All sera were processed using receptor-destroying 
enzyme to prevent non-specific inhibition, as described 
previously [11]. Prior to testing, 4 hemagglutinating units 
of virus was mixed 1:1 with a two-fold serial dilution 
series of serum and incubated at 37°C for 1 h. Following 
the incubation, 50 μL of 1% chicken erythrocytes in 
phosphate buffered saline (PBS) were added, mixed, 
incubated for 1 h at 4°C, and agglutination patterns read 
within 10 min. All tests were performed in “V” bottom 
microtiter plates and carried out in duplicate. The HI-titer 
was defined as the reciprocal of the last dilution of serum 
that completely inhibits hemagglutination.
RT-PCR
The nasal turbinates were gently rubbed with a wet 
cotton swab tip for 5 seconds to collect the swab samples. 
Before extraction, 0.5 mL Hank’s Balanced Salt Solution 
(HBSS) was added into the secretions in NS to adjust to 
1 mL volume. Samples were extracted from 200 μL as 
previously described [28]. Quantitative RT-PCR using 
Influenza A H7N9 virus nucleic acid fluorescent PCR 
rapid detection kits (DaAn Gene) was performed to 
amplify the HA and NA genes of the H7N9 virus, with 
18S rRNA serving as an internal control.
Virus titrations
We determined virus titrations as described by 
end-point titration in MDCK cells [29]. MDCK cells 
were inoculated with tenfold serial dilutions of culture 
supernatants. Cells were washed twice with PBS one 
hour after inoculation and cultured in 200 μL of infection 
medium (MEM containing 100 IU/mL penicillin, 100 μg/
mL streptomycin, 4% bovine serum albumin [fraction V, 
Gibco-BRL], and 4 μg/mL trypsin [Gibco-BRL]). Three 
days after inoculation, the supernatants of cell cultures 
were tested for agglutinating activity using turkey 
erythrocytes as an indicator of infection of the cells. 
Infectious virus titers were calculated from five replicates 
each of the homogenized tissue samples [27].
Histopathology of vital organs
All vital organs including the lungs (each lobe), 
spleen, intestines, liver, heart, kidney, olfactory bulb, and 
brain (anterior and posterior) from the three infection 
groups were harvested and immersed in 4% formaldehyde 
at least for 24 h. After fixation of the tissues and processing 
in paraffin wax, 4 μm sections were prepared and stained 
with H&E, examined and photographed.
Safety and toxicity evaluation of the split virus 
vaccine and MF59 adjuvant acute toxicity in rats
According to the WHO guidelines on vaccine safety 
evaluation (WHO technical reports, No. 927, 2005), the 
recommended dosing volume for each injection is no 
more than 30 μg/0.5 mL. Therefore, in this study, the 
highest single dose for the H7N9 avian influenza vaccine 
was 30 μg/0.5 mL. Forty Sprague Dawley (SD) rats were 
randomly assigned to four groups of 5/sex/group. Rats 
from groups 1-4 were intramuscularly injected with split 
H7N9 vaccine (30 μg/0.5 mL), split H7N9 vaccine (15 
μg/0.25 mL) and MF59 0.25 mL, MF59 (PBS 0.25 mL and 
MF59 0.25 mL), or NS 0.5 mL, respectively. The dose was 
administered by intramuscular injection, with a half dose 
infected in each hind limb. Animals were observed for 14 
days then fasted overnight prior to being necropsied.
Repeated dose toxicity in rats
A total of one hundred and twenty SD rats were 
randomly assigned to four groups of 15/sex/group. Rats 
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from groups 1-4 were intramuscularly injected with split 
H7N9 vaccine (30 μg/0.5 mL), split H7N9 vaccine (15 
μg/0.25 mL) and MF59 0.25 mL, M59 (PBS 0.25 mL 
and MF59 0.25 mL), or NS 0.5 mL, respectively, three 
times on days 1, 15, and 29, as described above. Ten rats 
of each sex per group and 5/sex/group rats underwent 
exsanguination from the abdominal aorta after isoflurane 
anesthesia and blood sample collection and were 
necropsied on day 32 (dosing phase), and day 57 (recovery 
phase), respectively.
Active systemic anaphylaxis test of split vaccine 
in guinea pigs
A total of 30 guinea pigs of both sexes were 
randomly assigned to five groups of 5/sex/group. For 
induction, groups 1-5 were intramuscularly injected 
with of 0.5 mL NS, 0.25 mL MF59 plus 0.25 mL PBS, 
30 μg/0.5 mL H7N9 vaccine, 30 μg/0.25 mL H7N9 
vaccine plus 0.25 mL MF59 and 5 mg/0.5 mL albumin, 
respectively, once every other day for a total of three 
injections (on days 1, 3, and 5). The challenge was 
performed on days 19 and 26. For the challenge, all 
animals were intravenously injected with doses twice 
those of the induction phase.
Clinical signs
Cage-side observation was conducted daily for the 
duration of the study period. Viability (morbidity and 
mortality) checks were performed twice daily. Detailed 
observations were conducted once pre-test, once prior to 
dosing on day 1, once at approximately 3 h post-dosing 
on day 1, and weekly thereafter during the observation 
period.
Body weight
Each animal was weighed once pre-test, once on day 
1 prior to dosing, once between 24 h and 48 h post-dosing, 
and once weekly throughout the remaining observation 
period.
Food consumption
Daily food consumption was measured once for all 
animals at day -2 during the pre-dosing period, and once 
weekly throughout the study from day -1 (except during 
fasting periods). Food was withdrawn overnight prior to 
scheduled blood collections for hematological, coagulation 
and serum biochemical determinations, urine collections, 
and scheduled necropsies.
Ophthalmological examination
Eyes were examined via slit lamp and indirect 
ophthalmoscope, once pre-dose, once halfway through the 
experimental period and once on the last day. A mydriatic 
(containing 1.0% tropicamide) was used to dilate the 
pupils for ophthalmology examination.
Local tolerance (injection site)
Injection sites had previously been clipped of hair 
and the injection site identified by indelible ink. The 
injection site was maintained free of excessive hair during 
the observation period. The injection site was scored using 
the Draize scoring system. The injection site was scored 
prior to each injection and at approximately 24 h and 48 
h after injection.
Body temperature
Body temperatures were measured once prior to day 
1 and pre-dose on day 1, once at approximately (± 30 min) 
3 h, 6 h, and 24 h post-dose and once prior to scheduled 
necropsy.
Hematological analysis
Blood samples for interim hematology, and 
clinical chemistry evaluation were obtained from the 
jugular vein of conscious animals. Blood samples for 
hematology, coagulation, and clinical chemistry were 
obtained from the abdominal aorta of animals at necropsy 
as a terminal procedure after isoflurane anesthesia. Five 
hundred microliters of blood were transfer into a CBC 
collection tube (K2EDTA, BD, USA) and analyzed using 
a hematology analyzer (Advia 2120, Seimens, USA). 
Additionally, 2 mL blood were transferred into a vacutainer 
(sodium citrate 3.2%, BD) and centrifuged at 3000 rpm for 
10 min. The plasma was isolated and used to determine 
aggregation time using a coagulometer (BE Compact-X, 
Behnk Elektronik, Germany). The following parameters 
were anlayzed: HCT (hematocrit), WBC (white blood cell 
count), HGB (hemoglobin concentration), RBC (red blood 
cell count), MCV (mean corpuscular volume), MCHC 
(mean corpuscular hemoglobin concentration), MCH 
(mean corpuscular hemoglobin), MPV (mean platelet 
volume), RDW (RBC distribution width), PLT (platelet 
count), NEUT (neutrophils), EOS (eosinophils), BASO 
(basophils), MONO (monocytes), LYMP (lymphocytes), 
retic (reticulocyte count), blood smear for cytology, PT 
(prothrombin time), FIB (fibrinogen), APTT (activated 
partial thromboplastin time).
Blood chemistry
Serum was isolated and used for biochemical 
analysis using an automatic serum analyzer (Hitachi 
7180, Japan). The following parameters were analyzed: 
ALT (alanine aminotransferase), CRE (creatinine), AST 
(aspartate aminotransferase), Ca (calcium), TP (total 
protein), P (phosphorus), ALB (albumin), GLB (globulin), 
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A/G (albumin/globulin ratio), TG (triglycerides), TCHO 
(total cholesterol), TBILNA (total bilirubin), ALP (alkaline 
phosphatase), Na (sodium), GGT (gamma glutamyl 
transferase), K (potassium), GLU (glucose), Cl (chloride), 
UREA (urea), CK (creatine kinase).
Urinalysis
During the final week of study, urinalysis was 
conducted to determine BIL (bilirubin), turbidity (color 
and clarity), KET (ketones), SG (specific gravity), BLO 
(occult blood), pH, PRO (protein), GLU (glucose) and 
URO (urobilinogen) using Multistix 10 SG reagent strips 
(Bayer, U.S.A.), and a urine analyzer (AX-4030, Aikelai, 
Japan). Microscopy studies were also performed for 
examination of sediment.
Necropsy findings
Scheduled terminated study animals underwent 
exsanguination from the abdominal aorta after isoflurane 
anesthesia. Gross observation was performed of the 
external surface, the cranial cavity, all orifices, and all 
thoracic and abdominal organs.
Organ weight
Following necropsy, the absolute and relative weight 
ratio (organ-to-body and organ-to-brain) of following 
organs was measured: adrenal glands, brain, heart, liver, 
kidneys, epididymis, lungs with main stem bronchi, 
ovaries, pituitary gland, prostate gland, thymus, spleen, 
testes, thyroid glands with parathyroid gland(s) and uterus 
(including cervix).
Histopathology
The following tissues were obtained: liver, kidney, 
adrenal gland, bone, aorta and bone marrow (sternum), 
bone (femur, including stifle joint), fallopian tubes, 
harderian gland, heart, injection sites, lungs with main 
stem bronchi, brain, spleen, epididymis, uterus, vagina, 
trachea, nerves (sciatic), esophagus, mammary glands 
(inguinal, female only), pituitary gland, prostate gland, 
salivary glands, lymph nodes (inguinal, mandibular, 
mesenteric and popliteal), thymus, stomach, urinary 
bladder, small/large intestine, eyes with optic nerve(s), 
ovaries, seminal vesicles, skin (inguinal), skeletal muscle 
(biceps femoris), spinal cord (cervical, thoracic, lumbar), 
testes, thymus, gross lesions, submandibular gland and 
pancreas. Tissues were trimmed and fixed in 10% neutral 
buffered formalin (NBF) with the following exceptions: 
eyes with optic nerves were fixed in 2.5% glutaraldehyde 
solution, and testes as well as epididymis were fixed in 
modified Davidson’s solution for 24 to 72 h before being 
transferred to 10% NBF. Tissues were removed from 
fixative, processed, embedded in paraffin, sectioned, 
stained with hematoxylin and eosin (H&E), and examined 
microscopically.
Statistical analysis
Males and females were analyzed separately. 
The viral load, virus titer, body weight, organ weight, 
biochemistry data and hematological data were analyzed 
for homogeneity of variance using Levene’s test. One-
way ANOVA was conducted for data shown to have 
homogeneity of variance. If homogeneity of variance 
and significance between test groups was confirmed, the 
Scheffe’s test was performed. If heterogeneity of variance 
and significance between test groups was determined, 
Dunnett’s test was conducted. All analysis were performed 
using the SPSS program.
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